| Cover Page | Jun. 07, 2022 |
| Document Information [Line Items] | |
| Document Type | 8-K |
| Entity Registrant Name | TENON MEDICAL, INC. |
| Entity Central Index Key | 0001560293 |
| Amendment Flag | false |
| Entity File Number | 001-41364 |
| Entity Tax Identification Number | 45-5574718 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 104 Cooper Court |
| Entity Address, City or Town | Los Gatos |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 95032 |
| City Area Code | 408 |
| Local Phone Number | 649-5760 |
| Document Period End Date | Jun. 7, 2022 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Entity Emerging Growth Company | true |
| Entity Ex Transition Period | false |
| Common Stock [Member] | |
| Document Information [Line Items] | |
| Title of 12(b) Security | Common Stock, par value $0.001 per share |
| Trading Symbol | TNON |
| Security Exchange Name | NASDAQ |
| Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
| Mar. 31, 2022 | Mar. 31, 2021 | |
| Income Statement [Abstract] | ||
| Revenue | $ 71 | $ 15 |
| Cost of sales | 275 | 11 |
| Gross (Loss) Profit | (204) | 4 |
| Operating Expenses | ||
| Research and development expenses | 562 | 87 |
| Sales and marketing expenses | 276 | 4 |
| General and administrative expenses | 1,037 | 102 |
| Total Operating Expenses | 1,875 | 193 |
| Loss from Operations | (2,079) | (189) |
| Other Income (Expense) | ||
| Gain on investments | 1 | |
| Interest expense | (274) | (11) |
| Other expense | (1) | (1) |
| Total Other Expense | (274) | (12) |
| Net Loss | (2,353) | (201) |
| Loss attributable to non-controlling interest | (1) | |
| Net Loss Attributable to Tenon Medical, Inc. | $ (2,353) | $ (200) |
| Net Loss Attributable to Tenon Medical, Inc. Per Share of Common Stock, Basic and diluted | $ (2.38) | $ (0.24) |
| Weighted-Average Shares of Common Stock Outstanding, Basic and diluted | 989,954 | 830,000 |
| Consolidated Statements of Comprehensive Loss: | ||
| Net loss | $ (2,353) | $ (201) |
| Unrealized loss on investments | ||
| Change in foreign currency translation adjustment | ||
| Total Comprehensive Loss | (2,353) | (201) |
| Comprehensive loss attributable to non-controlling interest | (1) | |
| Total comprehensive loss attributable to Tenon Medical, Inc. | $ (2,353) | $ (200) |
| Interim Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
| Current Assets | ||
| Cash and cash equivalents | $ 4,677 | $ 2,917 |
| Investments | 4,404 | |
| Accounts receivable | 64 | 76 |
| Inventory | 602 | 188 |
| Prepaid expenses | 82 | 87 |
| Total current assets | 5,425 | 7,672 |
| Fixed assets - net | 219 | 101 |
| Deposits | 41 | 41 |
| Operating lease right-of-use asset | 1,032 | 1,084 |
| Deferred offering costs | 428 | 374 |
| TOTAL ASSETS | 7,145 | 9,272 |
| Current Liabilities | ||
| Accounts payable | 425 | 478 |
| Accrued expenses | 970 | 1,088 |
| Current portion of operating lease liability | 227 | 202 |
| Convertible notes payable and accrued interest – net of debt discount of $14 and $31 at March 31, 2022 and December 31, 2021, respectively | 13,118 | 12,857 |
| Convertible notes payable and accrued interest due to related parties – net of debt discount of $1 and $2 at March 31, 2022 and December 31, 2021, respectively | 662 | 649 |
| Total current liabilities | 15,402 | 15,274 |
| Operating lease liability – net of current portion | 839 | 911 |
| Total Liabilities | 16,241 | 16,185 |
| Stockholders' Deficit | ||
| Common stock, $0.001 par value; 130,000,000 and 10,487,904 shares authorized at March 31, 2022 and December 31, 2021, respectively; 989,954 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively | 1 | 1 |
| Additional paid-in capital | 282 | 113 |
| Accumulated deficit | (22,928) | (20,575) |
| Accumulated other comprehensive income (loss) | (91) | (91) |
| Total stockholders' deficit | (22,736) | (20,552) |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' DEFICIT | 7,145 | 9,272 |
| Series A Convertible Preferred Stock [Member] | ||
| Convertible Preferred Stock | ||
| Convertible Preferred Stock | 12,367 | 12,367 |
| Series B Convertible Preferred Stock [Member] | ||
| Convertible Preferred Stock | ||
| Convertible Preferred Stock | $ 1,272 | $ 1,272 |
| Interim Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands | Mar. 31, 2022 | Dec. 31, 2021 |
| Convertible notes payable and accrued interest | $ 14 | $ 31 |
| Convertible notes payable and accrued interest due to related parties | $ 1 | $ 2 |
| Common stock par or stated value per share | $ 0.001 | $ 0.001 |
| Common stock shares authorized | 130,000,000 | 10,487,904 |
| Common stock shares issued | 989,954 | 989,954 |
| Common stock shares outstanding | 989,954 | 989,954 |
| Series A Convertible Preferred Stock [Member] | ||
| Temporary equity, par or stated value per share | $ 0.001 | $ 0.001 |
| Temporary equity shares authorized | 4,500,000 | 2,805,839 |
| Temporary equity shares issued | 2,550,763 | 2,550,763 |
| Temporary equity shares outstanding | 2,550,763 | 2,550,763 |
| Temporary equity liquidation preference | $ 3,891 | $ 3,891 |
| Series B Convertible Preferred Stock [Member] | ||
| Temporary equity, par or stated value per share | $ 0.001 | $ 0.001 |
| Temporary equity shares authorized | 491,222 | 491,222 |
| Temporary equity shares issued | 491,222 | 491,222 |
| Temporary equity shares outstanding | 491,222 | 491,222 |
| Temporary equity liquidation preference | $ 2,447 | $ 2,447 |
